{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:07Z","timestamp":1786982767247,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40265-026-02293-2","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:30:39Z","timestamp":1772764239000},"page":"753-758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Plozasiran: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1028-8594","authenticated-orcid":false,"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2293_CR1","unstructured":"Arrowhead Pharmaceuticals. Corporate presentation\u2014December 2025 [slides]. 2025. https:\/\/ir.arrowheadpharma.com\/static-files\/30b2fbe8-e8b9-4e03-ac03-bd276293430c. Accessed 7 Jan 2026."},{"issue":"2","key":"2293_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tcm.2019.03.001","volume":"30","author":"V Chyzhyk","year":"2020","unstructured":"Chyzhyk V, Brown AS. Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2020;30(2):80\u20135.","journal-title":"Trends Cardiovasc Med"},{"key":"2293_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2025.119114","volume":"403","author":"EA Brinton","year":"2025","unstructured":"Brinton EA, Eckel RH, Gaudet D, et al. Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Atherosclerosis. 2025;403:1\u201315.","journal-title":"Atherosclerosis"},{"key":"2293_CR4","unstructured":"Arrowhead Pharmaceuticals I. Arrowhead Pharmaceuticals announces FDA approval of REDEMPLO\u00ae (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) [media release]. 2025. https:\/\/arrowheadpharma.com."},{"key":"2293_CR5","unstructured":"Arrowhead Pharmaceuticals. REDEMPLO (plozasiran) injection, for subcutaneous use: US Prescribing information 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219947s000lbl.pdf. Accessed 8 Jan 2026."},{"key":"2293_CR6","unstructured":"Arrowhead Pharmaceuticals. Arrowhead receives FDA Fast Track designation for ARO-APOC3 [media release]. 20 Mar 2023. http:\/\/www.arrowheadpharma.com."},{"key":"2293_CR7","unstructured":"Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals announces Health Canada approval of REDEMPLO\u2122 (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) [media release]. 5 Jan 2026. https:\/\/arrowheadpharma.com."},{"key":"2293_CR8","unstructured":"Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals announces NMPA Approval of REDEMPLO\u00ae (plozasiran) for familial chylomicronemia syndrome (FCS) in China [media release]. 7 Jan 2026. https:\/\/arrowheadpharma.com."},{"key":"2293_CR9","unstructured":"Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals receives FDA Breakthrough Therapy designation for plozasiran [media release]. 10 Sep 2024. http:\/\/www.arrowheadpharma.com."},{"key":"2293_CR10","unstructured":"Arrowhead Pharmaceuticals. Arrowhead subsidiary Visirna sells rights to hypertriglyceridemia candidate plozasiran in Greater China to Sanofi [media release]. 1 Aug 2025. http:\/\/www.arrowheadpharma.com."},{"key":"2293_CR11","unstructured":"Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals receives Orphan Drug designation for ARO-APOC3 [media release]. 21 Jun 2019. http:\/\/www.arrowheadpharma.com."},{"key":"2293_CR12","unstructured":"Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals and Vivo Capital launch joint venture aimed at Greater China market [media release]. 25 Apr 2022. https:\/\/arrowheadpharma.com\/."},{"issue":"12","key":"2293_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200325","volume":"2","author":"D Gaudet","year":"2023","unstructured":"Gaudet D, Clifton P, Sullivan D, et al. RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia. NEJM Evid. 2023;2(12):EVIDoa2200325.","journal-title":"NEJM Evid"},{"issue":"19","key":"2293_CR14","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/j.jacc.2025.03.496","volume":"85","author":"CM Ballantyne","year":"2025","unstructured":"Ballantyne CM, Gaudet D, Rosenson RS, et al. Effect of targeting ApoC-III with plozasiran on lipoprotein particle size and number in hypertriglyceridemia. J Am Coll Cardiol. 2025;85(19):1839\u201354.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2293_CR15","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/jcph.70055","volume":"65","author":"J Ousey","year":"2025","unstructured":"Ousey J, Jomphe C, Ta A, et al. Population pharmacokinetic modeling of subcutaneous plozasiran in healthy volunteers and patients with familial chylomicronemia syndrome, severe hypertriglyceridemia, and mixed hyperlipidemia. J Clin Pharmacol. 2025;65(11):1485\u201396.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2293_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12933-025-02929-9","volume":"24","author":"F Wang","year":"2025","unstructured":"Wang F, You D, Niu X, et al. Safety, pharmacokinetics and pharmacodynamics of plozasiran in Chinese healthy volunteers. Cardiovasc Diabetol. 2025;24(1):399.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2293_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2409368","volume":"392","author":"GF Watts","year":"2025","unstructured":"Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med. 2025;392(2):127\u201337.","journal-title":"N Engl J Med"},{"issue":"10","key":"2293_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1161\/CIRCULATIONAHA.124.072860","volume":"151","author":"GF Watts","year":"2025","unstructured":"Watts GF, Hegele RA, Rosenson RS, et al. Temporal effects of plozasiran on lipids and lipoproteins in persistent chylomicronemia. Circulation. 2025;151(10):733\u20136.","journal-title":"Circulation"},{"issue":"Suppl 3","key":"2293_CR19","first-page":"e76","volume":"19","author":"R Hegele","year":"2025","unstructured":"Hegele R, Rosenson R, Goldberg I, et al. Plozasiran decreases the risk of acute pancreatitis and may improve quality of life in familial chylomicronemia syndrome [abstract no. 114 plus poster]. J Clin Lipidol. 2025;19(Suppl 3):e76.","journal-title":"J Clin Lipidol"},{"key":"2293_CR20","doi-asserted-by":"crossref","unstructured":"Watts G, Rosenson RS, Hegele RA, et al. A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE\u20141 year open label extension [abstract plus poster]. Eur Heart J. 2025;46(Suppl 1).","DOI":"10.1093\/eurheartj\/ehaf784.3969"},{"issue":"7","key":"2293_CR21","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9(7):620\u201330.","journal-title":"JAMA Cardiol"},{"key":"2293_CR22","doi-asserted-by":"crossref","unstructured":"Ballantyne C, Watts G, Rosenson R, et al. Plozasiran and triglyceride levels in hypertriglyceridemia: long-term efficacy and safety data from subjects in an open-label extension trial [abstract no. 4139852]. Circulation. 2024;150(Suppl 1).","DOI":"10.1161\/circ.150.suppl_1.4139852"},{"issue":"10","key":"2293_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):899\u2013912.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s40265-026-02334-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02293-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02293-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02293-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:06:24Z","timestamp":1779249984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02293-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2293"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02293-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-026-02334-w","URL":"https:\/\/doi.org\/10.1007\/s40265-026-02334-w","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}